The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Expert Rev Clin Pharmacol. 2010;13(4):563-580. Currently, isotretinoin is only licensed for the treatment of severe acne. However, in recent years, dermatologists have expanded their indications for ...

Acne vulgaris is one of the commonest skin disorders, which dermatologists treat and it mainly affects adolescents, though it may appear at any age. Acne by definition is multifactorial chronic ...

Please provide your email address to receive an email when new articles are posted on . All patients achieved complete clearance of their nodules by week 24. There were small, yet significant, ...

-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 This Phase III clinical trial is a randomized, double-blind, ...

Biofrontera Inc. has received patent approval for an updated formulation of Ameluz®, extending patent protection until December 2043. This formulation, which has been in use since FDA approval in 2024 ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis ...

-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, ...

Active ingredients: Clindamycin (as phosphate) 1.2%, benzoyl peroxide 2.5%; gel. Indication: Topical treatment of acne vulgaris. Pharmacology: Acanya gel combines the lincosamide antibiotic, ...